(Q34195628)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Randomised clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

Jean-francois Bergmann

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Andre Boonstra

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

J de Bruijne

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

D M Hotho

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

R J de Knegt

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C J Weegink

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

A A van Vliet

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J van de Wetering

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

S P Fletcher

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

L A Bauman

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

M Rahimy

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J R Appleman

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

J L Freddo

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

H L A Janssen

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

H W Reesink

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

26 June 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

443-453

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21707679%20AND%20SRC:MED&resulttype=core&format=json

Treating hepatitis C infection in liver transplant recipients

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Immunology of hepatitis B and hepatitis C virus infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Toll-like receptor control of the adaptive immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X

A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2011.04745.X